

Genetic Signatures Appoints Former Roche Diagnostics Executive Allison Rossiter as CEO

Genetic Signatures Limited [ASX:GSS] (“GSS” or the “Company”), a global molecular diagnostics company today announces that its Board of Directors has appointed Allison Rossiter, a highly experienced molecular diagnostics executive, to serve as CEO, based in Sydney, Australia.

Ms Rossiter has extensive global experience in the diagnostics industry and since 2003 has held several senior roles for Roche Diagnostics in Europe, North America and most recently Australia.

Since 2019, Ms Rossiter has been Managing Director of Roche Diagnostics, Australia which has annual turnover in excess of A\$250 million and 210 staff. As part of this role, she oversaw Roche’s efforts to provide diagnostics tests for the SARS-CoV-2 virus in Australia during the recent pandemic. Prior to this, Ms Rossiter was global Lifecycle Leader for molecular point-of-care products with Roche Molecular Systems based in the US. During her time in this role, she achieved 160% year-on-year growth with the placement of over 3000 systems. During her time with Roche, Ms Rossiter also had direct executive responsibility for sales and marketing efforts in Canada and the United Kingdom.

“I am over the moon to be able to bring my extensive and proven commercial acumen as well as my knowledge of product development, regulatory processes and clinical value to a company such as Genetic Signatures” said Allison Rossiter incoming CEO of Genetic Signatures. “It is an incredibly exciting time for GSS and I am honoured to take on this role at such a pivotal time for the company and the employees.”

Ms Rossiter is joining Genetic Signatures at a time when the Company is about to launch its first FDA-cleared **3base**[®] product, the *EasyScreen*[™] Gastrointestinal Parasite Detection Kit, into the US market. Ms Rossiter will commence her role as CEO of Genetic Signatures no later than the end of September 2024.

“We are delighted to secure an executive of Ms Rossiter’s calibre and experience as we commence our global expansion into the largest molecular diagnostics market, the United States” said Dr Nick Samaras, Chairman of the Board of Genetic Signatures. “Having spent the majority of her career with one of the world’s leading diagnostics company, including working extensively in North America, she is very well-placed to lead our efforts in this key market. This is a very exciting time for Genetic Signatures as we transition to commercialising our products and technology onto the global stage.”

Ms Rossiter's appointment as Chief Executive Officer will commence 30 September 2024, or an earlier date as mutually agreed. Please refer to Appendix A for details of Ms Rossiter's remuneration in relation to the appointment as CEO. On commencement of Ms Rossiter's appointment, Dr Neil Gunn, who has been acting as interim CEO, will continue his position as Non-Executive Director.

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr Neil Gunn
Interim Chief Executive Officer
neil.gunn@geneticsignatures.com

Karl Pechmann
Chief Financial Officer
karl.pechmann@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*™ brand. Genetic Signatures' proprietary MDx 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen*™ respiratory kits and the growing interest in its gastroenteritis products to further commercialise its 3base® technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.

APPENDIX A

The material terms of Ms Rossiter’s employment as Chief Executive Officer are summarised below:

KEY TERMS	DETAILS									
Appointment and commencement date	Ms Rossiter will be appointed as Chief Executive Officer of the company commencing no later than 30 Sept 2024.									
Term	Ms Rossiter’s appointment as Chief Executive Officer will commence on the commencement date and will continue until terminated in accordance with the Contract.									
Base remuneration	Based remuneration of A\$500,000 per annum, exclusive of superannuation.									
Hiring bonus	Ms Rossiter will receive a one-time hiring bonus of A\$250,000 payable upon commencement.									
Short Term Incentive	STI will be 100% of base remuneration for on-target performance. Exceptional performance may qualify for a total STI of up to 200% of base salary.									
Termination	Either party may terminate the contract on 3 months’ notice.									
Long Term Incentive	<p>Ms Rossiter will be granted 2,500,000 Options under the Genetic Signatures Limited Equity Incentive Plan (EIP). Options will be granted within 3 months of the commencement of employment. Exercise price – Price to be determined as 30 day VWAP immediately preceding the commencement date of employment.</p> <p>Vesting conditions</p> <table border="1"> <thead> <tr> <th>Tranche</th> <th>% of Options available to vest</th> <th>Vesting date</th> </tr> </thead> <tbody> <tr> <td>Tranche 1</td> <td>25%</td> <td>12 months from commencement date</td> </tr> <tr> <td>Remaining tranches</td> <td>1/36th</td> <td>Each subsequent month after the vesting of Tranche 1</td> </tr> </tbody> </table> <p>Once vested, Options must be exercised within 15 years of the award of the Options. In the event of cessation as an employee, Ms Rossiter will have up to 30 days to exercise any vested Options, otherwise all unexercised vested Options and unvested Options are forfeited.</p>	Tranche	% of Options available to vest	Vesting date	Tranche 1	25%	12 months from commencement date	Remaining tranches	1/36 th	Each subsequent month after the vesting of Tranche 1
Tranche	% of Options available to vest	Vesting date								
Tranche 1	25%	12 months from commencement date								
Remaining tranches	1/36 th	Each subsequent month after the vesting of Tranche 1								